Of note, earlier studies showed that the systemic administration of bevacizumab caused an increase in the frequency of CD45dim, CD133+, VEGFR2+ EPCs in BC patients not responding to the therapy, while a reduction could not always be observed in those who did not show any change in disease progression [78]. The gene discussed is KDR; the disease is breast cancer.